Welcome to Roche Foundation Medicine.

This site is not intended to provide medical advice and/or treatment guidance. It is produced by Roche as the licensed distributor of Foundation Medicine products outside of the US.

Please select an option:

You are leaving

Dear visitor,
Please note that you are now leaving www.foundationmedicine.my

 

 

Alt

Order now

 

Ordering process

A simple, convenient ordering process

Ordering a Foundation Medicine service is a simple, convenient process and our turnaround times (time from receipt of sample at our laboratory in United States to receiving Foundation Medicine report: less than 2 weeks for FoundationOne Liquid CDx, 14 days for FoundationOne CDx, 21 days for FoundationOne Heme) are comparable to less comprehensive tests.

Ordering a Foundation Medicine service

1 Order test 2 Prepare sample 3 Send the sample to Foundation Medicine 4 Analysis of the sample and evaluationof the results 5 Receive patient report

 

 

 

Specimen instructions

Formalin-fixed paraffin-embedded (FFPE) specimens, including cut slide specimens, are acceptable

Two 8.5 mL peripheral
blood specimens
 

Peripheral blood, bone marrow aspirate or FFPE tissue specimens may be used with ≥20% tumour cell content

 

 

 

PD-L1 supplementary test

PD-L1 by IHC can be ordered as a supplemental test

PD-L1 expression (based on IHC) does not correlate with tumour mutational burden (TMB). Therefore, PD-L1 testing and TMB status could complement each other for guiding cancer immunotherapy treatment.1–3 PD-L1 by IHC can be ordered as a supplemental test.

 

 

 

Customer support

Customer support to facilitate patient care

We provide customer support built on an extraordinary wealth of knowledge, expertise and dedication to help you provide the best possible care.

Expert pathology review of sample analysis Specialist bioinformatics team identifies clinically relevant mutations Oncologists and genomics experts curate reports based on latest literature Customer support team the process Medical team is available to support you with interpretation of the report on request

IHC, immunohistochemistry; PD-Ll, programmed death-ligand 1; TMB, Tumour Mutational Burden.
References
  1. Kamzi S. Presented at ESMO Immuno Oncology Congress 2017; Geneva, Switzerland: Poster no. 35P.
  2. Rizvi H et al. J Clin Oncol 2018; 36: 633–641.
  3. Hellmann MD et al. Cancer Cell 2018; 33: 843–852.e4.